Drug Profile
Milvexian - Bristol-Myers Squibb
Alternative Names: BMS 177; BMS-986177; JNJ-3093; JNJ-70033093Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Johnson & Johnson Innovative Medicine
- Class Antiarrhythmics; Antithrombotics; Aza compounds; Chlorobenzenes; Macrocyclic compounds; Pyrimidinones; Small molecules; Triazoles; Vascular disorder therapies
- Mechanism of Action Factor XIa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute coronary syndromes; Atrial fibrillation; Stroke
- Phase II Venous thromboembolism
- Phase I Unspecified
- No development reported Thrombosis
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 10 Sep 2023 Pharmacokinetics data from phase-I trial in healthy volunteers presented at the American College of Clinical Pharmacology Annual Meeting (ACCP-2023)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Thrombosis(In volunteers) in Netherlands (PO)